Month: June 2015

Chimeric Antigen Receptor (CAR) T cell Therapy: An Innovative Technology of Living Cancer medication

Posted on

T-cells-killing-cancerWe designed CAR T cells to overcome a number of problems in getting T cells to attack Cancer”-says Eshhar, after the development of first CAR-T cells (1989).




CAR-T Technologies and History of Innovations

Ever so often in the history of immunotherapy, there comes a breakthrough that takes cancer research across a frontier into a new era. With the development of first CAR-T cells started in the late 1990s and the emergence of new CARs generations with promising study results targeting cancer indications has given a big blow to the immunotherapy market.

Even with these encouraging preliminary findings, the adverse events associated with CAR-T cell therapy are the major drawbacks. To overcome this problem, companies started focusing on the incorporation of safety switches to existing CARs, which are designated to eliminate CAR-T cells in the event of toxicity. The research studies are ongoing with the safety switches, but the success rates are still ambiguous.

Current CAR-T Technology Scenario-Showing promising Results

Researchers are studying ways to improve on the positive results obtained to date by the advancement in the existing CAR technology. First generation CARs having single signaling domain showed very limited clinical benefits. To provide specific targeting and improved function of T-cells, recently, second and third generation CARs have been engineered to include additional stimulatory domains, usually derived from the intracytoplasmatic portion of costimulatory molecules. 

Other such technologies are based on safety switches to minimize the adverse events associated with CAR-T cell therapy. Although, some of the companies are conducting their research studies on safety switches with CARs. One of the CAR-T player, Bellicum Pharmaceuticals has developed “safety switch” by the genetic modification of CAR-T cell to kill itself, when exposed to a drug called Rimiducid. The company will start a clinical trial in 2016, incorporating CaspaCIDe safety switch technology with BPX-401, which is a CAR-T product targets CD19 on the surface of blood cancer cells for leukaemia and lymphomas. Other companies like Juno, Intrexon/ Ziopharm and Cellectis are also developing safety switches with their technologies.

CAR-T TechnologiesThere are 8 different technologies innovated by different leading CAR-T companies, including CIDeCAR and GoCAR-T technology of Bellicum Pharmaceuticals, CAR-eACT technology of Kite Pharma, Use of meganucleases & TALENs by Cellectis and CAR modified C.I.K. cells technology of Formula Pharmaceuticals. More than 50 % of leading firms are using different CAR-T generations.



DelveInsight Expert Reviews

With the entrance of Bio-Pharmaceutical companies, mainly focusing on the advancement of CAR-T technologies are working aggressively to overcome the darkness of cancers. Indeed, more research is needed, that will take nearly 4 to 5 years, before CAR T-cell therapy can be a routine option for patients with cancer. Overall, conditions are currently favorable for the emerging firms to groom their CAR-T business beyond the negatives. 

Written by Vikas Soni, Trainee at DelveInsight

For more information about CAR-T cell technology, please read the full report: Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis 2015

For more information on this Report, mail us at


Chimeric Antigen Receptor (CAR) T-cell Therapy Landscape; A Report

Posted on Updated on

In the field of oncology, no other approach is as attentive as Immunotherapy. Renewed interest in immunotherapy CAR-Thas been driven by Chimeric Antigen Receptor (CAR) T-cell therapy. This emerging approach is (CAR) T-cell technology which is showing great promise in immunotherapy. There are 35+ products in pipeline and 40+ companies are active in this field.

With the advancement of (CAR) T-cell technology showing more safety and efficacy, the companies dealing with immunotherapy are grabbing the opportunity to enter in this new emerging market by the routes of collaborations and acquisitions.

What is CAR-T Cell Therapy?

CAR T-cells are the engineered T-cells to express chimeric antigen receptor (CARs) which identifies specific antigens of a target-cell. CARs are specifically designed receptors, which graft specificity into an immune effector cell. This therapy acts as genetic modification of T-cells from cancer patients by gene transfer of chimeric antigen receptors (CARs) to recognize molecules on cancer cells without relying on MHC presentation. This adoptive T-cell therapy harnesses the power of the immune system to target and kill tumor cells.

CAR-T Therapy Landscape


Most of the companies are dealing with the conventional CAR T-cell technology, targeting CD19 antigen of lymphoma cells, which is occupying more than 50% share in target antigens. Meanwhile, the companies are also investing on the studies targeting 25+ different antigens of cancer cells as well as the firms are coming up with 8+ different technologies to enhance the safety and efficacy of the CAR T-cell therapy.

Attractive Pipeline

There are 35+ pipeline products and 40+ companies including small and big firms are actively involved. Out of 40 companies, 15+ leading companies are involved with their product in clinical phases. Novartis with the Phase-II product CTL019 is leading the race.


With 25+ collaborations happened in recent years, Juno Therapeutics (JUNO) has inked a massive $727 million R&D deal with Editas Medicine that is considered as greatest deal in this segment. 7+ Research institutes and 12+ small firms having core CAR T-cell technologies partnered with some of the leading companies for the development of the CAR-T cell therapy.


As CAR-T technology are showing most promising results in cancer studies, companies are conducting their Pre-clinical and clinical trial studies with 18+ Oncology indications, in which B-cell malignancies, Lymphoma & Leukemia are the prominent one.

CAR-T Cells Therapy Info-graph

CAR-T Therapy

DelveInsight Expert Comments

CAR T-cell therapy will drive the future of Immunotherapy to promising heights. The companies with lagging attention to this approach are already behind. The deals will continue to increase the market size and continued desperation to get on surviving with the key risks on this competitive landscape, numerous players could end up basking in reflected glory.

Written by Vikas Soni, Trainee at DelveInsight

Upcoming DelveInsight Report on CAR-T Cell Therapies-Landscape, 2015

For more information on this Report, mail us at

Lets share our knowledge, provide your comments in the comment section

DelveInsight Hiring at Analyst and Associate Analyst Position

Posted on Updated on

DelveInsight Hiring!!!
Looking for Passionate Candidates
Mail your updated Resume to


Profile Offered: Analyst (2-4 years Experienced)

Education: M. Pharma/ Biotech/MBA Biotech/B.Tech/

Roles and Responsibilities:

  • Excellent editing, verbal and written communications skills, as a good deal of the job
    of “Consultant” lies in appropriately messaging our work for clients.
  • Ability to take initiative to work independently, but should also be able to follow directions and be confident about asking for guidance when necessary.
  • Ability to look beyond smaller details to find broader connections and opportunities for
    a project. Our work depends upon marrying the expertise of team members from
    a number of different disciplines and pulling out the essential, big-picture strategies.
  • Ability to multi-task, stay organized amidst distractions, communicate directly with project managers, and produce high-quality written work.
  • Must be comfortable with deadlines.
  • 2-4 years related work experience. Salary will commence with experience, with opportunity for growth and professional advancement.


Profile Offered: Associate Analyst (Freshers)

Education: M. Pharma/ Biotech/MBA Biotech/B.Tech/

Roles and Responsibilities:

  • Conduct market research through primary and secondary sources according to the client needs
  • Maintain knowledge databases and making new databases.
  • Compile, analyze and present data in the form of reports to clients.
  • Responsible for strategy development, weekly updates and project delivery.
  • Customer centric problem solving skills within their own realm of expertise.

Core Competencies

  • Strong verbal and oral communication skills
  • Team player and excellent interpersonal skills
  • Logical and creative thinker with enthusiasm and a desire to get involved

Technical Skills

  • Sound subject knowledge
  • Ability to work on diverse technical domains (related to the field of life sciences)

 About Us

DelveInsight is a Business Consultant company and serve as a Knowledge partner across the value chain of Pharmaceutical Industry. DelveInsight provides cutting-edge Market and Pipeline Intelligence, Competitive Intelligence and also an API intelligence knowledge partner for the Pharma and biotech sector, helping clients to quantify market events and evaluate their impact on the valuation of products, portfolios and companies. We combine industry expertise with innovation by collecting, analyzing and communicating to deliver critical information to leading decision makers in the Approved drugs market, Active Pharmaceutical (API) market, Generic market and Drug’s research and development. We help Drug developing companies, Generics and API manufacturing companies to strategize and identify the right thrust areas and potential customers for their existing and new products.

At DelveInsight, we believe what we do matters. We are passionate about our work, inspired by the impact it has on our business and our customers. As a team, we believe in winning as one – collaborating to reach shared goals, and developing through challenging and meaningful experiences. The pharmaceuticals market is in its growth stage and we are uniquely positioned to successfully endeavour the dimensions of the fast growing market by providing cutting-edge market and pipeline information, to our clients.

Outbreak of Companies Challenging New Pathways for Treatment of Pulmonary Arterial Hypertension

Posted on


Drugs with better pharmacodymics and improved treatment algorithm with antiproliferative and anti-inflammatory treatments are needed!

Pulmonary arterial hypertension (PAH) is rare lung disorder affecting pulmonary arteries. It is a fatal disease associated with the vasoconstriction and vascular remodeling that is characterized by progressive increase of pulmonary pressure and resistance leading to right heart failure. In most of the cases this disease is diagnosed in the late stage classified by WHO as Class III and IV. PAH is categorized as group one under pulmonary hypertension. History reports the emergence of this disease back in 1891 with the concept of hemodynamics. In 1973, World Health Organization (WHO) categorized the pressure rise in pulmonary arteries as primary and secondary pulmonary hypertension. Although it is a rare disease but it has estimated prevalence of 15-50 cases per million. Epoprostenol, a prostacyclin analog was the first drug to provide treatment for pulmonary arterial hypertension which was followed by improved therapies in oral forms acting as phosphodiesterase V inhibitors and endothelin receptor antagonists (ERAs). These therapies are designed to stimulate relaxation of pulmonary arteries but are not directly targeting vascular remodeling.

Research over last five years

Recently within past 5 years, there have been major advances in the treatment option for PAH with better understanding of pathophysiology. Newer paradigms have paved way for the future development of novel therapeutics targets. Endothelial dysfunction has become a major area of interest as therapeutic target for treatment of PAH. Other targets explored recently include Tyrosine Kinase (TK) inhibitors which involve growth factors such as bFGF, PDGF and EGF; Rho-kinases in signaling pathways, Dehydroepiandrosterone, miRNA, Gene therapy and Stem cell therapy. Combination therapies of approved drugs are also used in the clinical trials but it remains unknown whether it will prove to be more effective than other drugs. More than 20 drugs have reached in the clinical trials for the treatment of PAH indication.

Pharmaceutical Companies Researching in PAH

Novarts AG, GlaxoSmithKline PLC, Pfizer Inc and Eli Lilly & Co. are few giant bio-pharmaceutical companies whose products are in phase III and acts on novel therapeutic targets. Gilead Biosciences is coming up with the combination therapy in phase III. These all companies are expected to provide huge competition in the market to some of the already marketed drugs such as Tracleer (bosentan) which is set to go off-patent in US and Europe in 2015 and 2017. Other companies to look up to in future include Arena Pharmaceuticals, Inc., Dong-A PharmTech Co., Ltd. and Reata Pharmaceuticals. Celladon Corporation, miRagen Therapeutics, Inc., Silence Therapeutics and Northern Therapeutics, Inc. are other companies which are establishing themselves for the treatment of PAH by targeting gene, stem cell and micro RNA.

DelveInsight Expert Comments

The current treatments have shown symptomatic improvements but they do not provide the evidence of long term survival. The future clinical trials for PAH looks complex and challenging as it is an orphan disease deep insight knowledge of molecular biology. Drugs with better pharmacodymics and improved treatment algorithm with antiproliferative and anti-inflammatory treatments are needed that will target the pulmonary disease more specifically.

Written by Tarun Jain, Associate Analyst at DelveInsight

Upcoming Report:Pulmonary Arterial Hypertension – Competitive Landscape, Market & Pipeline Analysis, Forecasted Market Size 2015-2020

For more information on this Report, mail us at

Lets share our knowledge, provide your comments in the comment section